# Relationship of Interleukin-1Î² Blockade With Incident

Annals of Internal Medicine
169, 535
DOI: 10.7326/m18-1167

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Management of complex gout in clinical practice: Update on therapeutic approaches. Best Practice and Research in Clinical Rheumatology, 2018, 32, 813-834. | 1.4 | 12 |
| 2 | IL-1Î² blockade prevents gout attacks. Nature Reviews Rheumatology, 2018, 14, 622-622. | 3.5 | 0 |
| 3 | Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1510-1519. | 1.1 | 57 |
| 4 | Vascular Consequences of Hyperuricemia and Hypouricemia. Rheumatic Disease Clinics of North America, 2019, 45, 453-464. | 0.8 | 8 |
| 5 | The IL-1 family of cytokines and receptors in rheumatic diseases. Nature Reviews Rheumatology, 2019, 15, 612-632. | 3.5 | 247 |
| 6 | Pigment Nephropathy: Novel Insights into Inflammasome-Mediated Pathogenesis. International Journal of Molecular Sciences, 2019, 20, 1997. | 1.8 | 14 |
| 7 | Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. European Heart Journal, 2019, 40, 1778-1786. | 1.0 | 148 |
| 8 | Relationship of Interleukin-1Î² Blockade With Incident Gout and Serum Uric Acid Levels. Annals of Internal Medicine, 2019, 170, 737. | 2.0 | 2 |
| 9 | New evidence on the role of inflammation in CVD risk. Current Opinion in Cardiology, 2019, 34, 418-423. | 0.8 | 26 |
| 10 | The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. Lancet Rheumatology, The, 2019, 1, e220-e228. | 2.2 | 38 |
| 11 | Repurposing antidiabetic medications for gout: the potential of sodium glucose co-transporter 2 inhibitors. Lancet Rheumatology, The, 2019, 1, e197-e199. | 2.2 | 2 |
| 12 | Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes. Journal of Cardiovascular Pharmacology, 2019, 74, 297-305. | 0.8 | 23 |
| 13 | Gout. Nature Reviews Disease Primers, 2019, 5, 69. | 18.1 | 326 |
| 14 | Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation. Clinical Rheumatology, 2019, 38, 263-265. | 1.0 | 11 |
| 15 | Antiâ€inflammatory therapy for atherosclerosis: interpreting divergent results from the <scp>CANTOS</scp> and <scp>CIRT</scp> clinical trials. Journal of Internal Medicine, 2019, 285, 503-509. | 2.7 | 32 |
| 16 | Prevention and treatment of gout. Nature Reviews Rheumatology, 2019, 15, 68-70. | 3.5 | 23 |
| 17 | Effects of Interleukin-1Î² Inhibition on Incident Anemia. Annals of Internal Medicine, 2020, 172, 523. | 2.0 | 37 |
| 18 | Effects of Interleukin-1Î² Inhibition on Incident Hip and Knee Replacement. Annals of Internal Medicine, 2020, 173, 509-515. | 2.0 | 84 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Targeting cardiovascular inflammation: next steps in clinical translation. European Heart Journal, 2021, 42, 113-131. | 1.0 | 186 |
| 20 | Advances in our understanding of gout as an auto-inflammatory disease. Seminars in Arthritis and Rheumatism, 2020, 50, 1089-1100. | 1.6 | 35 |
| 21 | Prophylaxis of Acute Arthritis at Initiation of Urate-Lowering Therapy in Gout Patients. , 0, , . | | 4 |
| 22 | Inflammasomes contributing to inflammation in arthritis. Immunological Reviews, 2020, 294, 48-62. | 2.8 | 97 |
| 23 | Endothelial Pannexin 1 Channels Control Inflammation by Regulating Intracellular Calcium. Journal of Immunology, 2020, 204, 2995-3007. | 0.4 | 55 |
| 24 | Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study. Arthritis Research and Therapy, 2020, 22, 86. | 1.6 | 21 |
| 25 | The role of interleukin-1 family members in hyperuricemia and gout. Joint Bone Spine, 2021, 88, 105092. | 0.8 | 37 |
| 26 | Cortisol on Circadian Rhythm and Its Effect on Cardiovascular System. International Journal of Environmental Research and Public Health, 2021, 18, 676. | 1.2 | 75 |
| 27 | Coronary artery disease: â€˜goutâ€™ in the artery?. European Heart Journal, 2021, 42, 2761-2764. | 1.0 | 10 |
| 28 | Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. Circulation Research, 2021, 128, 1728-1746. | 2.0 | 238 |
| 29 | Targeting inflammation in atherosclerosis â€" from experimental insights to the clinic. Nature Reviews Drug Discovery, 2021, 20, 589-610. | 21.5 | 459 |
| 30 | Canakinumab for secondary prevention of coronary artery disease. Future Cardiology, 2021, 17, 427-442. | 0.5 | 10 |
| 31 | Gout. Lancet, The, 2021, 397, 1843-1855. | 6.3 | 418 |
| 32 | ACR management guidelines for the treatment of gout: Whatâ€™s new and whatâ€™s controversial. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 129-133. | 0.2 | 6 |
| 33 | Features and Outcomes of Microcrystalline Arthritis Treated by Biologics: A Retrospective Study. Rheumatology and Therapy, 2021, 8, 1241-1253. | 1.1 | 4 |
| 34 | A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares. Arthritis and Rheumatology, 2021, 73, 1533-1542. | 2.9 | 45 |
| 35 | Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the <scp>EMPAâ€REG OUTCOME</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 135-141. | 2.2 | 29 |
| 36 | Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies. Atherosclerosis, 2021, 335, 98-109. | 0.4 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Medications for gout and its comorbidities: mutual benefits?. Current Opinion in Rheumatology, 2021, 33, 145-154. | 2.0 | 2 |
| 39 | Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout. Nauchno-Prakticheskaya Revmatologiya, 2019, 56, 760-766. | 0.2 | 8 |
| 40 | PROSPECTS FOR USING COLCHICINE IN MEDICINE: NEW EVIDENCE. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 183-190. | 0.2 | 10 |
| 41 | Therapy with canakinumab for gout. Nauchno-Prakticheskaya Revmatologiya, 0, 56, 41-48. | 0.2 | 6 |
| 43 | Consensus on patients with hyperuricemia and high cardiovascular risk treatment. Systemic Hypertension, 2019, 16, 8-21. | 0.1 | 22 |
| 44 | Medications, Therapeutic Modalities, and Regimens Used in the Management of Rheumatic Diseases. , 2021, , 205-243. | | 0 |
| 45 | Crystal-Induced Arthritis. , 2022, , 147-210. | | 0 |
| 46 | Pathophysiology of Gout. Seminars in Nephrology, 2020, 40, 550-563. | 0.6 | 32 |
| 47 | Safety Evaluation of Natural Drugs in Chronic Skeletal Disorders: A Literature Review of Clinical Trials in the Past 20 years. Frontiers in Pharmacology, 2021, 12, 801287. | 1.6 | 9 |
| 48 | Whatâ€™s new on the front-line of gout pharmacotherapy?. Expert Opinion on Pharmacotherapy, 2022, 23, 453-464. | 0.9 | 5 |
| 49 | Adherence to 2020 to 2025 Dietary Guidelines for Americans and the Risk of New-Onset Female Gout. JAMA Internal Medicine, 2022, 182, 254. | 2.6 | 21 |
| 50 | IL-6, IL-1Î², and MDA Correlate with Thrombolysis in Myocardial Infarction (TIMI) Risk Score in Patients with Acute Coronary Syndrome. Recent Advances in Inflammation & Allergy Drug Discovery, 2022, 15, 71-79. | 0.4 | 0 |
| 51 | Gout Is Associated With Worse Post-PCI Long-Term Outcomes. Cardiovascular Revascularization Medicine, 2022, 41, 166-169. | 0.3 | 1 |
| 52 | Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis. Acta Diabetologica, 2022, 59, 783-791. | 1.2 | 14 |
| 53 | Causal mediation analysis of the relationship of canakinumab's effect against subsequent gout flares and highâ€sensitivity Câ€reactive protein in <scp>CANTOS</scp>. Arthritis Care and Research, 2021, , . | 1.5 | 3 |
| 54 | Effects of vitamin C supplementation on gout risk: results from the Physiciansâ€™ Health Study II trial. American Journal of Clinical Nutrition, 2022, 116, 812-819. | 2.2 | 4 |
| 55 | TET2-mutant clonal hematopoiesis and risk of gout. Blood, 2022, 140, 1094-1103. | 0.6 | 57 |
| 56 | The human inflammasomes. Molecular Aspects of Medicine, 2022, 88, 101100. | 2.7 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 57 | Targeting innate immunity-driven inflammation in CKD and cardiovascular disease. Nature Reviews Nephrology, 2022, 18, 762-778. | 4.1 | 51 |
| 58 | Immersion in Water Between 20-30<sup>o</sup>C Mediated Inflammations Marker to Reduced Pain Among Indonesian With Gout Arthritis: A Community-Based Randomized Controlled Trial. Biological Research for Nursing, 0, , 109980042211328. | 1.0 | 0 |
| 59 | Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022. Systemic Hypertension, 2022, 19, 5-22. | 0.1 | 5 |
| 60 | Resolution of the Council of Excperts (16th June, 2022): Therapy of gouty arthritis with an IL-1 inhibitor (anakinra). Nauchno-Prakticheskaya Revmatologiya, 2022, 60, 638-641. | 0.2 | 2 |
| 61 | Geneâ€"Diet Interactions: Beyond Duelling Views of Gout Pathogenesis. Arthritis and Rheumatology, 2023, 75, 869-871. | 2.9 | 2 |
| 62 | The Singapore Experience With Uncontrolled Gout: Unmet Needs in the Management of Patients. Cureus, 2023, , . | 0.2 | 0 |
| 63 | Innate Immunity System in Patients With Cardiovascular and Kidney Disease. Circulation Research, 2023, 132, 915-932. | 2.0 | 8 |
| 64 | Anti-inflammatory Therapy for Cardiovascular Disease. , 2024, , 224-235.e1. | | 0 |
| 72 | Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nature Reviews Drug Discovery, 2024, 23, 43-66. | 21.5 | 3 |
| 73 | Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis: Lessons for Cholesterol from the Land of Gout. Contemporary Cardiology, 2023, , 321-349. | 0.0 | 0 |